CAU Scholar's Space: Na, Dong Hee

Detailed Information

Na, Dong Hee (나동희)

대학원 (글로벌혁신신약학과)

Research Area: 약물전달시스템, 펩타이드/단백질 제제 연구, 나노의약품, Dug Delivery System, Peptide/Protein Formulation, Nanomedicine

Tel 02-820-5677
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

HPLC:6||COVID19:4||Validation:4||assay:4||Stability:3||Assay:3||Sepsis:3||NETosis:3||validation:2||Dendrimer:2||Korean Pharmacopoeia (KP XI):2||PEGylation:2||Cosmetics:2||Immunoglobulin G:2||Nanomedicine:2||Nanoparticles:2||Albumin nanoparticles:2||Chemical chaperone:1||Curcumin:1||Cystamine:1||Cysteamine:1||Cytokine storm:1||DNase:1||DNaseI:1||DSPE:1||Determination:1||Diabetes:1||Didodecyldimethylammonium bromide:1||DoE:1||Doxil:1||Drug delivery:1||Drug delivery system:1||Endoplasmic reticulum stress:1||Exendin4:1||Fluorometholone:1||Formulation:1||Fusidate Sodium:1||GLP1 receptor:1||GLP1R agonist:1||Ginsenoside:1||Highpressure homogenizer:1||Highspeed homogenizer:1||Inflammation:1||Ionpairing agent:1||KSLW:1||Korean Pharmacopoeia(KP XI):1||Liposomal drug products:1||Liposome:1||Lipsticks:1||Lungselective nanohybrids:1||Microglia activation:1||Microparticles:1||NFkappa B signaling:1||NLY01:1||Nano differential scanning fluorimetry:1||Nanoarchitecture:1||Nanodrug delivery:1||Nanospheres:1||Nanotechnology:1||Neuroprotective effect:1||Neurotoxin stability:1||Ophthalmic suspension:1||Permaton red:1||Poly(lactic acid):1||Poly(lacticcoglycolic acid):1||Protein aggregation:1||Pulmonary delivery:1||Pulmonary drug delivery:1||Reactive astrocytes:1||Response surface methodology:1||Reversedphase HPLC:1||Reversedphase highperformance liquid chromatography:1||Rheumatoid arthritis:1||SETD6:1||Selfassembly:1||Severe COVID19:1||Sizeexclusion chromatography (SEC):1||Spray freeze drying:1||Spray freezedrying:1||TH17Treg:1||TRAIL:1||Tablet dosage form:1||Tamoxifen:1||Tar color:1||Tauroursodeoxycholic acid:1||Tetrahydrozoline hydrochloride:1||Tramadol hydrochloride injection:1||Transforming growth factor βinduced protein:1||Trehalose:1||Triflusal:1||accelerated in vitro release testing methods:1||albumin nanoparticles:1||ampicillin sodium:1||antioxidant activity:1||aptamers:1||bioavailability:1||biopharmaceuticals:1||biopolymeric microparticles:1||capsules:1||contact time:1||cytokine storm:1||diosmin capsule:1||drug release testing:1||drying technology:1||ferritin:1||high performance liquid chromatography:1||highperformance liquid chromatography (HPLC):1||hydrophilic polymer:1||in vitro release:1||in vitroin vivo correlation:1||loperamide hydrochloride:1||molecular weight:1||mucoadhesion:1||nonbiologic drugs:1||occluding:1||pharmacokinetics:1||poly(lactidecoglycolide):1||protein stability:1||s disease:1||sepsis:1||small organic molecules:1||solubilization:1||sulbactam sodium:1||surface area:1||synthetic peptides:1||tablet dosage form:1||thickness:1||thioctic acid:1||25hydroxycholesterol:1||βcarotene:1||Acetylation inhibitory peptide:1||Adalimumab:1||Aggregation:1||Albumin:1||Alzheimer&#8217:1||Amino acid excipient:1||Amino acids:1||Antibody:1||Antibody formulation:1||Antioxidant activity:1||Apoptosis:1||Autoimmune diseases:1||Bioinspiration:1||Biophysical characterization:1||Botulinum neurotoxin A complex:1||Capsule:1||

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE